Citi Starts Coverage of Six Major European Drugmakers, Favors AstraZeneca and Novartis
Citi has opened coverage on six leading European pharmaceutical groups with a constructive sector view. The bank rates AstraZeneca, Novartis and Roche as Buy, while GSK, Sanofi and Novo Nordisk receive Neutral ratings. Citi points to an unusually deep late-stage pipeline and expects resilient earnings growth driven by new product launches that larg…